Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Effect of the methanol extraction residue of Bacillus Calmette‐Guerin in advanced Hodgkin's disease
Cancer, Volume 49, No. 11, Year 1982
Notification
URL copied to clipboard!
Description
One‐hundred‐ninety‐six patients with Stage III and IV Hodgkin's disease were prospectively randomized to receive either treatment with the methanol extraction residue of Bacillus Calmette‐Guerin (MER/BCG) or no immunotherapy. Prior to the MER/BCG randomization, patients received six courses of induction and two years of maintenance chemotherapy so that a group with a presumptively low tumor burden could be established. Only patients achieving a complete remission were evaluated. During the first two years of immunotherapy, the MER/BCG group had a relapse frequency twice that of controls. The overall crude relapse frequency and disease‐free survival were similar between the two treatment groups. The MER/BCG dose schedule used in this study was associated with a high frequency of unacceptable toxicity. Ulcerations of greater than 1 cm occurred in one‐third of the patients with associated pain, fever, and occasional lymphadenopathy. A high degree of patient noncompliance (36%) was observed. Age (P = 0.002), prior radiotherapy (P = 0.032), and chemotherapy (P = 0.044) were prognostic factors found to significantly influence remission duration. These factors were balanced between patients treated with immunotherapy and those who were not. MER/BCG therapy did not significantly delay or prevent relapse. Copyright © 1982 American Cancer Society
Authors & Co-Authors
Cooper, Miles Robert
United States, Winston Salem
Wake Forest University School of Medicine
Pajak, Thomas F.
United States, Scarsdale
Operations Office
Nissen, Nis Iversen
Denmark, Copenhagen
Finsen Institute
Brunner, Kurt W.
Switzerland, Bern
University Hospital Bern
Stutzman, Leon
United States, Buffalo
Roswell Park Cancer Institute
Bank, Arthur
United States, New York
Newyork-presbyterian/columbia University Irving Medical Center
Falkson, Geoffrey G.
South Africa, Pretoria
University of Pretoria
Barker, Barbara E.
United States, Providence
Rhode Island Hospital
Haurani, Farid I.
United States, Philadelphia
Thomas Jefferson University Hospital
Richards, Frederick C.
United States, Winston Salem
Wake Forest University School of Medicine
Gottlieb, Arlan Jay
United States, Syracuse
Upstate Medical University Hospital
Holland, James F.W.
United States, New York
Icahn School of Medicine at Mount Sinai
Statistics
Citations: 12
Authors: 12
Affiliations: 11
Identifiers
Doi:
10.1002/1097-0142(19820601)49:11<2226::AID-CNCR2820491104>3.0.CO;2-R
ISSN:
0008543X
e-ISSN:
10970142
Research Areas
Cancer
Health System And Policy
Study Design
Randomised Control Trial